Stock MTNB MATINAS BIOPHARMA HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Matinas BioPharma Holdings, Inc.

Equities

MTNB

US5768101058

Real-time Estimate Cboe BZX
Other stock markets
 12:31:16 27/06/2024 am IST 		5-day change 1st Jan Change
0.158 USD +1.74% Intraday chart for Matinas BioPharma Holdings, Inc. +2.50% -25.99%
24/06 Matinas Biopharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in Its Oral Mat2203 Compassionate/Expanded Use Access Program CI
18/06 Transcript : Matinas BioPharma Holdings, Inc. - Special Call

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
GL
Matinas Biopharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in Its Oral Mat2203 Compassionate/Expanded Use Access Program
CI
Transcript : Matinas BioPharma Holdings, Inc. - Special Call
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
GL
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
AQ
Matinas Biopharma Holdings, Inc.'s Oral MAT2203 Featured in Fireside Chat
CI
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
GL
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
AQ
Transcript : Matinas BioPharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
GL
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
GL
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
GL
In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
AQ
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
GL
In Vivo Efficacy of Matinas BioPharma?s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
CI
Matinas BioPharma Prices $10 Million Registered Direct Offering
GL
Matinas BioPharma Prices $10 Million Registered Direct Offering
AQ
Transcript : Matinas BioPharma Holdings, Inc., 2023 Earnings Call, Mar 27, 2024
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MTNB Stock
  4. News Matinas BioPharma Holdings, Inc.